查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2005002

正子斷層掃描（PET）市場：按產品類型、應用、最終用戶和技術分類的全球市場預測，2026-2032年

Positron Emission Tomography Market by Product Type, Application, End User, Technology - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，正子斷層掃描 (PET) 市場價值將達到 29.2 億美元，到 2026 年將成長至 31.2 億美元，到 2032 年將達到 45.7 億美元，複合年成長率為 6.61%。

主要市場統計數據
基準年 2025 29.2億美元
預計年份：2026年 31.2億美元
預測年份 2032 45.7億美元
複合年成長率 (%) 6.61%

全面概述正子斷層掃描（PET）作為多維度成像技術，如何影響醫療領域的臨床決策和策略投資。

正子斷層掃描（PET）是現代分子影像的基石，它能夠提供獨特的視角，深入了解支撐診斷、治療計劃和治療監測的生理和代謝過程。 PET 的應用使其不再只是一種診斷手段，而是一項引領精準醫療的綜合技術，它整合了先進的硬體、放射化學和軟體主導的分析。檢測器設計、影像重建演算法和放射性示踪劑化學的進步，使其臨床效用從腫瘤學擴展到神經病學、心臟病學以及其他新的適應症，從而重塑了診療路徑和研究重點。

探討技術、臨床和商業性因素的整合如何加速 PET 能力的發展，擴大示蹤劑組合，並重塑服務模式。

正子斷層掃描（PET）領域正經歷一場變革性的轉變，這場轉變正在重新定義臨床實踐、技術發展和經營模式。從類比檢測器系統到全數位化、飛行時間（TOF）平台的過渡，提高了靈敏度、空間解析度和定量精度，從而縮短了掃描時間並減少了放射性示踪劑的劑量，同時又不影響診斷的可靠性。同時，放射化學的進步拓展了可用示蹤劑的種類，使其不再局限於氟代脫氧葡萄糖，而是涵蓋了澱粉樣蛋白、 Tau蛋白、前列腺特異性抗原（PSA）和其他分子標靶靶向藥物，從而開闢了新的臨床途徑。

對 2025 年前的累積關稅調整如何重塑 PET 設備採購、示蹤劑生產經濟和跨境供應鏈策略進行分析評估。

到了2025年，美國實施的一系列關稅措施的累積影響已對PET供應鏈、採購週期和跨境合作產生複雜的後果。影響進口掃描器組件、檢測器材料和配件的關稅調整增加了某些硬體配置的到貨成本，迫使採購團隊重新評估總擁有成本（TCO）並探索替代籌資策略。此外，用於放射性示蹤劑製造的化學品和原料的關稅正在影響集中式和分散式示蹤劑製造的成本結構，進而影響企業對自建迴旋加速器和區域生產網路的投資決策。

詳細的細分洞察揭示了產品選擇、臨床應用、最終用戶需求和技術水準如何結合起來決定 PET 的實施和營運策略。

要了解PET的發展趨勢，需要仔細考慮產品、應用、最終用戶和技術等各個維度如何相互作用，進而影響市場需求和臨床效用。從產品類型來看，設備和放射性示蹤劑發揮互補作用。專用PET掃描儀和PET/CT掃描儀決定了影像和處理能力，而FDG等放射性示蹤劑則決定了診斷特異性和臨床工作流程。在設備選擇方面，通常需要在PET/CT系統提供的高通量和整合的解剖資訊與專用PET平台提供的特殊靈敏度和檢查室最佳化之間進行權衡。放射性追蹤劑的可用性和物流方面的考量因素，決定了影像中心網路中首選的臨床適應症。

區域分析揭示了美洲、歐洲、中東和非洲以及亞太地區的基礎設施、報銷方案和研究重點如何影響PET的取得和策略機會。

PET部署和容量分佈的區域趨勢反映了美洲、歐洲、中東和非洲以及亞太地區醫療基礎設施、報銷框架和研究重點的差異。在美洲，完善的三級醫療網路和整合的腫瘤臨床路徑使得PET部署集中在都市區，同時私人診斷實驗室和大學醫院也積極參與其中。報銷模式和臨床指引的採納影響著腫瘤和神經病學等適應症的優先順序，而與放射化學中心的接近性則影響著示蹤劑的可用性和當日檢測的可行性。

本文重點介紹了硬體創新、放射化學優勢、軟體整合和服務模式如何決定 PET 的策略優勢，並探討了公司之間的競爭與合作趨勢。

PET生態系中各公司之間的競爭格局取決於技術差異化、放射化學能力、整合服務交付以及拓展臨床應用範圍的策略夥伴關係。硬體供應商專注於檢測器創新、與CT和MRI系統的互通性以及能夠減少停機時間並最佳化掃描儀利用率的全生命週期服務模式。同時，放射性示蹤劑生產商和放射性藥物藥局則在示蹤劑種類、生產可靠性和物流效率方面展開競爭，尤其是在短壽命同位素領域，因為時間和配送網路對臨床操作至關重要。設備供應商和示踪劑供應商之間的合作日益普遍，從而能夠提供捆綁式解決方案，簡化醫療機構的採購和營運整合。

為領導者提供切實可行的策略建議，以最佳化對 PET 的技術投資，確保示蹤劑供應，增強分析能力，並提高營運韌性。

產業領導者若想充分利用PET日益成長的臨床意義，應採取一套平衡的策略措施，涵蓋技術選擇、營運韌性和相關人員協作等面向。首先，將資本規劃與臨床優先事項結合，可確保設備投資與腫瘤科、神經科和心臟科所需的處理能力和診斷範圍相符。領導者應評估數位PET和飛行時間（TOF）技術是否能提供足夠的臨床和工作流程優勢，從而證明在高運作中心部署的合理性，同時保留適用於低運作環境的成本效益高的模擬方案。其次，透過本地生產夥伴關係或管理供應協議實現放射性示踪劑供應多元化，將降低營運風險，並支持整個轉診網路的一致服務。

採用透明且多方面的調查方法，結合專家訪談、技術文獻整合和監管比較分析，以確保獲得可靠的見解。

本報告的研究採用多方面方法，結合了定性專家對話和對技術文獻、監管通知及臨床指南趨勢等第二手資料的整合。一手資訊來源包括對臨床醫生、醫學物理學家、放射化學家、醫療系統採購經理和技術部門主管的結構化訪談，揭示了技術應用的促進因素、營運限制和創新重點。二級資訊來源包括同行評審文章、會議論文集、監管出版刊物和示踪劑的專業書籍，記錄了檢測器技術、放射性示踪劑化學和圖像分析技術的進步。

將技術進步、示踪劑擴展和策略舉措與 PET 在所有醫療環境中的永續臨床應用聯繫起來，從而實現明確的整合。

這份執行概要強調，由於技術日趨成熟、示蹤劑種類不斷豐富以及服務模式不斷演進，PET正處於一個轉折點。這些因素共同推動了PET在臨床應用領域的拓展，同時也增加了其操作的複雜性。硬體能力、放射化學物流、軟體驅動的分析以及政策環境之間的相互作用，將繼續影響PET在所有醫療機構的部署模式。透過策略性地加強示踪劑供應多元化、有針對性地採用新技術以及投資於分析和人才培養，醫療機構能夠在控制成本和營運風險的同時，充分發揮PET的臨床潛力。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 正子斷層掃描（PET）市場：依產品類型分類

  • 裝置
    • 專用PET掃描儀
    • PET/CT掃描儀
  • 放射性示踪劑

第9章 正子斷層掃描（PET）市場：依應用領域分類

  • 循環系統
  • 神經病學
  • 腫瘤學

第10章 正子斷層掃描（PET）市場：依最終用戶分類

  • 診斷中心
  • 醫院
  • 研究機構

第11章 正子斷層掃描（PET）市場：依技術分類

  • 模擬PET
  • 數字PET
  • 飛行時間PET

第12章 正子斷層掃描（PET）市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 正子斷層掃描（PET）市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 正子斷層掃描（PET）市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國正子斷層掃描（PET）市場

第16章：中國正子斷層掃描（PET）市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Advanced Accelerator Applications
  • Canon Medical Systems Corporation
  • Cardinal Health, Inc.
  • Curium Pharma
  • General Electric Company
  • IBA Worldwide
  • Jubilant DraxImage Inc.
  • Koninklijke Philips NV
  • Lantheus Medical Imaging, Inc.
  • Mediso Medical Imaging Systems Kft.
  • Molecure SA
  • Neusoft Medical Systems Co., Ltd.
  • Nordion Inc.
  • Positron Corporation
  • Samsung Electronics Co., Ltd.
  • Siemens Healthineers AG
  • Sofie Biosciences, Inc.
  • United Imaging Healthcare Co., Ltd.
  • Yangzhou Kindsway Biotech Co., Ltd.
Product Code: MRR-742BD5183E5A

The Positron Emission Tomography Market was valued at USD 2.92 billion in 2025 and is projected to grow to USD 3.12 billion in 2026, with a CAGR of 6.61%, reaching USD 4.57 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.92 billion
Estimated Year [2026] USD 3.12 billion
Forecast Year [2032] USD 4.57 billion
CAGR (%) 6.61%

A comprehensive orientation to positron emission tomography as a multi-dimensional imaging modality shaping clinical decision-making and strategic investment across healthcare

Positron emission tomography represents a cornerstone of contemporary molecular imaging, delivering unique insights into physiological and metabolic processes that underpin diagnosis, treatment planning, and therapeutic monitoring. This introduction frames PET not merely as a diagnostic modality but as an integrative technology that converges hardware sophistication, radiochemistry, and software-driven analytics to inform precision medicine pathways. Advances in detector design, image reconstruction algorithms, and radiotracer chemistry have broadened clinical utility beyond oncology to neurology, cardiology, and emerging indications, thereby reshaping care pathways and research priorities.

As imaging departments and research institutes evaluate capital allocation and clinical workflows, PET's role in enabling targeted therapies and reducing diagnostic uncertainty has become increasingly salient. Concurrently, the ecosystem supporting PET has evolved to include service models for tracer supply, scanner-as-a-service offerings, and vendor partnerships that extend lifecycle support. This dynamic environment necessitates that stakeholders balance clinical value with operational complexity, supply chain resilience, and regulatory compliance. The following sections deploy a strategic lens to examine transformative shifts, policy impacts, segmentation-specific dynamics, regional variations, competitive behavior, and actionable recommendations that will guide healthcare providers, technology developers, and investors as they navigate the PET landscape.

An exploration of the converging technological, clinical, and commercial forces that are accelerating PET capability, expanding tracer portfolios, and reshaping service models

The PET landscape is undergoing transformative shifts that are redefining clinical practice, technology development, and commercial models. The transition from analog detector systems to fully digital and time-of-flight capable platforms has driven improvements in sensitivity, spatial resolution, and quantitative accuracy, enabling shorter acquisition times and reduced radiotracer dose without compromising diagnostic confidence. In parallel, advancements in radiochemistry have expanded the palette of available tracers beyond fluorodeoxyglucose to include agents targeting amyloid, tau, prostate-specific membrane antigen, and other molecular targets, thereby opening new clinical pathways.

Concurrently, software and artificial intelligence are layering additional value by automating image processing, enhancing lesion detection, and providing decision support that augments clinician workflows. These capabilities are increasingly integrated into vendor ecosystems, where post-processing and analytics become differentiators. Operationally, the landscape is shifting toward service-centric models, including managed tracer supply and remote system maintenance, which reduce capital barriers for smaller diagnostic centers and promote wider adoption. Regulatory harmonization and cross-border collaboration on tracer production are also evolving, with stakeholders navigating complex approval pathways to scale innovative agents. Taken together, these shifts create a more versatile and clinically potent PET environment while also raising new considerations related to access, reimbursement, and workforce readiness.

An analytical assessment of how cumulative tariff adjustments through 2025 have reshaped PET equipment sourcing, tracer production economics, and cross-border supply chain strategies

The cumulative effects of United States tariff measures enacted through 2025 have introduced a complex set of influences across PET supply chains, procurement cycles, and cross-border collaboration. Tariff adjustments that affect imported scanner components, detector materials, and accessory goods have increased landed costs for certain hardware configurations, prompting procurement teams to reassess total cost of ownership and to explore alternative sourcing strategies. In addition, tariffs on chemicals and raw materials used in radiotracer production have implications for the cost structure of centralized and decentralized tracer manufacturing, influencing decisions about in-house cyclotron investments and regional production networks.

Beyond direct cost implications, tariffs have affected strategic partnerships and vendor selection, as suppliers adjust manufacturing footprints and logistics networks to mitigate exposure. This has led some technology providers to diversify manufacturing locations and to strengthen local service capabilities in key markets to preserve competitive positioning. For clinical operations, increased costs can translate into extended equipment replacement cycles, prioritization of high-throughput clinical indications, and closer scrutiny of utilization metrics to justify capital expense. At the same time, regulatory and customs complexities introduced by tariff changes have accentuated the need for robust compliance and trade expertise within organizations that import critical components or that engage in cross-border clinical trials. In response, stakeholders are accelerating supply chain transparency initiatives, exploring nearshoring options, and engaging in collaborative purchasing arrangements to preserve access to advanced imaging capabilities under shifting trade conditions.

In-depth segmentation insights revealing how product choices, clinical applications, end-user needs, and technology tiers coalesce to determine PET adoption and operational strategy

Understanding PET dynamics requires close attention to how product, application, end user, and technology dimensions interact to shape demand and clinical utility. From a product type perspective, equipment and radiotracers serve complementary roles: dedicated PET scanners and PET/CT scanners define imaging capability and throughput, while radiotracers such as FDG determine diagnostic specificity and clinical workflows. Equipment decisions often trade off between the high throughput and integrated anatomical context provided by PET/CT systems and the specialized sensitivity and station optimization of dedicated PET platforms. Radiotracer availability and logistical considerations can dictate the clinical indications that are prioritized within a network of imaging sites.

Application segmentation reveals differing clinical drivers; cardiology prioritizes perfusion and viability assessments, neurology emphasizes neurodegenerative disease characterization and seizure localization, and oncology leverages PET for staging, therapy selection, and response assessment. These application needs translate into distinctive utilization patterns across end users: diagnostic centers focus on outpatient workflows and referral-driven imaging volumes, hospitals integrate PET into multidisciplinary care pathways and inpatient workups, and research institutes emphasize protocol flexibility and novel tracer evaluation. Technology choices intersect with these dynamics, as analog PET systems may be retained for cost-sensitive settings while digital PET and time-of-flight platforms are adopted where the clinical value of higher resolution and faster throughput justifies investment. Consequently, strategic planning must account for how product type, application, end user, and technology preferences collectively influence procurement, training, and service models across diverse care settings.

A regional analysis that maps how infrastructure, reimbursement, and research priorities in the Americas, Europe Middle East & Africa, and Asia-Pacific shape PET access and strategic opportunities

Regional dynamics in PET adoption and capability distribution reflect differences in healthcare infrastructure, reimbursement frameworks, and research emphasis that vary across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, well-developed tertiary care networks and integrated oncology pathways have supported concentrated PET deployment in urban centers, accompanied by strong involvement from private diagnostic providers and academic medical centers. Reimbursement models and clinical guideline adoption influence the prioritization of indications such as oncology and neurology, while proximity to radiochemistry hubs affects tracer availability and the viability of same-day assays.

Across Europe, Middle East & Africa, heterogeneous regulatory regimes and diverse healthcare financing models create a mosaic of PET access levels; several markets demonstrate advanced clinical integration supported by national reimbursement policies and established radiopharmacy networks, whereas others are constrained by logistical and capital limitations. In Asia-Pacific, rapid investment in healthcare infrastructure, expanding clinical trial activity, and growing incidence of oncology and neurodegenerative disease are driving the expansion of PET services, often supported by government-led initiatives and public-private partnerships that accelerate facility build-outs and tracer production. These regional differences have implications for equipment manufacturers, tracer suppliers, and service providers, each of which must tailor engagement strategies to local regulatory requirements, referral patterns, and channel structures to effectively support adoption and sustainable operations.

Competitive and collaborative company trends highlighting how hardware innovation, radiochemistry strength, software integration, and service models define strategic advantage in PET

Competitive dynamics among companies in the PET ecosystem are defined by technology differentiation, radiochemistry capabilities, integrated service offerings, and strategic partnerships that extend clinical reach. Hardware providers focus on detector innovation, interoperability with CT and MRI systems, and lifecycle service models that reduce downtime and optimize scanner utilization. At the same time, radiotracer manufacturers and radiopharmacies compete on tracer variety, production reliability, and logistics performance, particularly for short-lived isotopes where timing and distribution networks are critical to clinical operations. Collaborative arrangements between equipment vendors and tracer suppliers are increasingly common, enabling bundled solutions that simplify procurement and operational integration for healthcare providers.

Companies are also innovating in software, adding quantification tools and AI-driven workflows that improve throughput and standardize reporting. Service providers offering managed supply or scanner-as-a-service models are expanding their footprint to lower barriers for smaller centers. Strategic alliances with academic centers and participation in multicenter trials help firms validate new tracers and technologies, accelerating clinical acceptance. For buyers, these dynamics mean evaluating partners not only on product specifications but also on the strength of service networks, regulatory expertise, and the ability to support clinical validation and reimbursement pathways. As the ecosystem matures, competitive advantage increasingly accrues to organizations that can offer end-to-end solutions encompassing hardware, tracer supply, analytics, and sustained operational support.

A pragmatic set of strategic recommendations for leaders to optimize technology investments, secure tracer supply, enhance analytics, and strengthen operational resilience in PET

Industry leaders seeking to capitalize on PET's expanding clinical relevance should pursue a balanced set of strategic actions that address technology choices, operational resilience, and stakeholder engagement. First, aligning capital planning with clinical priorities ensures that equipment investments match the throughput and diagnostic breadth required by oncology, neurology, and cardiology services. Leaders should evaluate whether digital PET and time-of-flight technologies deliver sufficient clinical and workflow benefits to justify adoption in high-volume sites while maintaining cost-effective analog options for lower-volume settings. Second, securing radiotracer supply through diversified sourcing, local production partnerships, or managed supply agreements reduces operational risk and supports consistent service delivery across referral networks.

Third, investing in software and analytics that streamline image processing, reporting, and data integration will enhance clinician adoption and enable value demonstration to payers. Fourth, implementing rigorous supply chain transparency and trade compliance practices will mitigate the operational impacts of tariff and policy changes. Fifth, fostering collaborative relationships with academic centers, clinical trial consortia, and payer stakeholders can accelerate evidence generation needed for guideline inclusion and reimbursement. Finally, building workforce competencies through targeted training for technologists, physicists, and interpreting physicians ensures that organizations can extract the full clinical value of advanced PET capabilities. These recommendations, taken together, create a pragmatic roadmap for organizations to expand PET services in a sustainable and clinically impactful way.

A transparent multi-method research methodology combining expert interviews, technical literature synthesis, and regulatory comparative analysis to ensure robust insights

The research underlying this report integrates a multi-method approach that combines qualitative expert engagement with secondary synthesis of technical literature, regulatory filings, and clinical guideline developments. Primary inputs include structured interviews with clinicians, medical physicists, radiochemists, health system procurement leaders, and technology executives to surface adoption drivers, operational constraints, and innovation priorities. Secondary sources encompass peer-reviewed publications, conference proceedings, regulatory agency publications, and tracer monographs that document advances in detector technology, radiotracer chemistry, and image analysis techniques.

Analytical steps involved thematic synthesis of qualitative inputs, technology capability mapping, and cross-regional regulatory comparison to elucidate adoption patterns and strategic considerations. Attention was given to validation through triangulation across practitioner interviews, technical documentation, and published clinical evidence. Care was taken to ensure factual accuracy by referencing up-to-date regulatory guidance and peer-reviewed findings on tracer performance and detector characteristics. Ethical considerations and data provenance were observed in primary data collection, with interview subjects engaged under agreed confidentiality terms. The methodology emphasizes transparency and reproducibility, enabling decision-makers to understand the evidence base that informs the insights and recommendations presented in the report.

A conclusive synthesis that connects technological progress, tracer expansion, and strategic action to the sustainable clinical integration of PET across care settings

This executive synthesis underscores that PET is at an inflection point driven by technological refinement, broader tracer portfolios, and evolving service models that together expand clinical applications and operational complexity. The interplay between hardware capability, radiochemistry logistics, software-enabled analytics, and policy environments will continue to shape adoption patterns across care settings. Strategic responses that emphasize diversified tracer supply, targeted technology deployment, and investment in analytics and workforce development will enable providers to realize PET's clinical promise while managing cost and operational risk.

Stakeholders who integrate evidence-generation activities, such as participation in multicenter trials and local validation studies, will be better positioned to influence guideline adoption and reimbursement decisions. Furthermore, proactive supply chain and trade compliance strategies can mitigate disruption stemming from tariff and policy shifts. Ultimately, the organizations that succeed will be those that combine clinical leadership with operational agility and collaborative partnerships, translating PET's technical advances into sustainable improvements in patient care and research capability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Positron Emission Tomography Market, by Product Type

  • 8.1. Equipment
    • 8.1.1. Dedicated Pet Scanners
    • 8.1.2. Pet/Ct Scanners
  • 8.2. Radiotracers

9. Positron Emission Tomography Market, by Application

  • 9.1. Cardiology
  • 9.2. Neurology
  • 9.3. Oncology

10. Positron Emission Tomography Market, by End User

  • 10.1. Diagnostic Centers
  • 10.2. Hospitals
  • 10.3. Research Institutes

11. Positron Emission Tomography Market, by Technology

  • 11.1. Analog Pet
  • 11.2. Digital Pet
  • 11.3. Time-Of-Flight Pet

12. Positron Emission Tomography Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Positron Emission Tomography Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Positron Emission Tomography Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Positron Emission Tomography Market

16. China Positron Emission Tomography Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Advanced Accelerator Applications
  • 17.6. Canon Medical Systems Corporation
  • 17.7. Cardinal Health, Inc.
  • 17.8. Curium Pharma
  • 17.9. General Electric Company
  • 17.10. IBA Worldwide
  • 17.11. Jubilant DraxImage Inc.
  • 17.12. Koninklijke Philips N.V.
  • 17.13. Lantheus Medical Imaging, Inc.
  • 17.14. Mediso Medical Imaging Systems Kft.
  • 17.15. Molecure S.A.
  • 17.16. Neusoft Medical Systems Co., Ltd.
  • 17.17. Nordion Inc.
  • 17.18. Positron Corporation
  • 17.19. Samsung Electronics Co., Ltd.
  • 17.20. Siemens Healthineers AG
  • 17.21. Sofie Biosciences, Inc.
  • 17.22. United Imaging Healthcare Co., Ltd.
  • 17.23. Yangzhou Kindsway Biotech Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES POSITRON EMISSION TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DEDICATED PET SCANNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DEDICATED PET SCANNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DEDICATED PET SCANNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PET/CT SCANNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PET/CT SCANNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PET/CT SCANNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY RADIOTRACERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY RADIOTRACERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY RADIOTRACERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY ANALOG PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY ANALOG PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY ANALOG PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DIGITAL PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DIGITAL PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DIGITAL PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TIME-OF-FLIGHT PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TIME-OF-FLIGHT PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TIME-OF-FLIGHT PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 102. GCC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GCC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. GCC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 105. GCC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. GCC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GCC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. G7 POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. G7 POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. G7 POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 123. G7 POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. G7 POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. G7 POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. NATO POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. NATO POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. NATO POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 129. NATO POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. NATO POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. NATO POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES POSITRON EMISSION TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)